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Abstract
Cone rod dystrophies (CRDs) (prevalence 1/40,000) are inherited retinal dystrophies that
belong to the group of pigmentary retinopathies. CRDs are characterized by retinal pigment
deposits visible on fundus examination, predominantly localized to the macular region. In
contrast to typical retinitis pigmentosa (RP), also called the rod cone dystrophies (RCDs)
resulting from the primary loss in rod photoreceptors and later followed by the secondary loss
in cone photoreceptors, CRDs reflect the opposite sequence of events. CRD is characterized
by primary cone involvement, or, sometimes, by concomitant loss of both cones and rods that
explains the predominant symptoms of CRDs: decreased visual acuity, color vision defects,
photoaversion and decreased sensitivity in the central visual field, later followed by progressive
loss in peripheral vision and night blindness. The clinical course of CRDs is generally more severe
and rapid than that of RCDs, leading to earlier legal blindness and disability. At end stage,
however, CRDs do not differ from RCDs. CRDs are most frequently non syndromic, but they
may also be part of several syndromes, such as Bardet Biedl syndrome and Spinocerebellar
Ataxia Type 7 (SCA7). Non syndromic CRDs are genetically heterogeneous (ten cloned genes
and three loci have been identified so far). The four major causative genes involved in the
pathogenesis of CRDs are ABCA4 (which causes Stargardt disease and also 30 to 60% of
autosomal recessive CRDs), CRX and GUCY2D (which are responsible for many reported cases
of autosomal dominant CRDs), and RPGR (which causes about 2/3 of X-linked RP and also an
undetermined percentage of X-linked CRDs). It is likely that highly deleterious mutations in
genes that otherwise cause RP or macular dystrophy may also lead to CRDs. The diagnosis of
CRDs is based on clinical history, fundus examination and electroretinogram. Molecular
diagnosis can be made for some genes, genetic counseling is always advised. Currently, there is
no therapy that stops the evolution of the disease or restores the vision, and the visual prognosis
is poor. Management aims at slowing down the degenerative process, treating the complications
and helping patients to cope with the social and psychological impact of blindness.
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Cone rod dystrophies (CRDs)
Definition and diagnosis criteria
CRDs are inherited retinal dystrophies that belong to the
pigmentary retinopathies group.
Functional signs and symptoms
• Decrease in the visual acuity is the earliest symptom
• Photophobia also occurs early
• Frequent dyschromatopsia
• Night blindness occurs later
Visual field
• Central scotoma appears first, preventing fluent reading
• Patchy losses of peripheral vision follow
• Severe loss of vision occurs earlier than in retinitis pig-
mentosa (RP)
Fundus
• Normal looking macula or fine macular lesions and pal-
lor of the optic disc may be the only signs at early stage
• Pigmentary deposits resembling bone spicules, fre-
quently in macular area
• Attenuation of the retinal vessels
• Waxy pallor of the optic disc
• Various degrees of retinal atrophy
Electroretinogram (ERG)
• Implicit time (between a- and b-wave peaks) shift at the
30-Hz flicker responses, along with delayed a- and b-wave
single flash photopic response are early signs before
amplitude reduction
• Dramatic decrease of amplitudes of both a- and b-waves
• Predominant involvement of photopic (cones) over sco-
topic (rods) responses
Epidemiology
Prevalence of CRDs is estimated at 1/40,000 (thus, CRDs
are ten times less frequent than RP) [1].
Clinical description
Non syndromic cone rod dystrophies
CRDs present first as a macular disease or as a diffuse
retinopathy with predominance of the macular involve-
ment. In contrast to the symptoms of the rod cone dystro-
phies (RCDs, typical retinitis pigmentosa) resulting from
predominant rod involvement, i.e. night blindness and
loss of peripheral vision, the clinical signs of CRDs reflect
the predominant involvement of cones, which leads to
decreased visual acuity and loss of sensitivity in the central
visual field. This fits the original description of the CRD
entity in which cone loss precedes rod degeneration.
However, in some cases, diffuse retinopathy affects simul-
taneously cones and rods, resulting in both night blind-
ness and loss of visual acuity. These cases may also be
considered as CRDs, although they overlap with other
entities (see differential diagnosis). In general, CRDs are
more severe than RCDs because the loss of patients'
autonomy occurs earlier. It is convenient to describe two
stages in the disease course of CRD.
In the first stage, the main symptom is decreased visual
acuity, which is usually discovered at school, in the first
decade of life, and which does not significantly improve
with spectacles. Patients often have a noticeable deviated
gaze to project images on parafoveal regions of their retina
that are less damaged. Along with this symptom, there are
intense photophobia and a variable degree of dyschro-
matopsia. In contrast, night blindness is not mentioned
by patients or, when present, is never as prominent as the
decrease in visual acuity. Visual field testing shows central
scotomas, while periphery is spared. As a result, patients
have no difficulties to move. Fundus examination shows
pigment deposits and various degrees of retinal atrophy in
the macular region (Figure 1). Retinal vessels are usually
normal or moderately attenuated. The optic disc is often
pale at early stages, particularly on the temporal side,
which accounts for the macular fibre bundle. At this stage,
the question is to differentiate CRDs from macular dystro-
phies such as Stargardt disease, cone dystrophies and
other rare macular conditions. Additional investigations
help the diagnosis. First, fluorescein angiography and fun-
dus autofluorescence show that the peripheral retina is
also involved with heterogeneity in the fluorescence, but
to a lesser extent than the macula. Second, the elec-
troretinogram (ERG) shows a shift in implicit time of
cone responses, followed by a decrease in both cone and
rod responses. Cone responses are more severely affected
than rod responses.
In the second stage, night blindness becomes more
apparent and the loss in the peripheral visual field
progresses. Therefore, patients have difficulties to move
autonomously. In addition, visual acuity continues to
decrease to a level where reading is no longer possible.Page 2 of 7
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legally blind (visual acuity <1/20), even though large
parts of the peripheral visual field remain preserved.
Syndromic cone rod dystrophies
There are a few syndromes in which retinal degeneration
characteristically features CRDs rather than typical RP.
• Bardet Biedl syndrome (BBS) is an autosomal recessive
disease with a prevalence ranging from 1/13,500 to 1/
60,000. It associates retinal dystrophy with postaxial poly-
dactyly, obesity, hypogenitalism, mental retardation or
mild psychomotor delay, and renal abnormalities that can
lead to renal failure. The retinal dystrophy is classically
described as a RCD but many variants have been reported
with a prominent macular involvement (Figure 2), indi-
cating a CRD [2]. In fact, BBS patients have the diffuse
type of CRD. In our experience, they always have macular
involvement, with decreased visual acuity, photophobia
and foveomacular hyperfluorescence on fluorescein angi-
ography. The diagnosis of retinal dystrophy is often estab-
lished in the first decade of life and legal blindness is
reached before 20 years of age, but there are moderate
forms of the disease. Diagnosis may be difficult when the
clinical picture is incomplete. In this case, the presence of
a CRD is an important sign. Twelve BBS genes encoding
proteins involved in the cilium structure have been
reported so far.
• Spinocerebellar Ataxia Type 7 is an autosomal domi-
nant spinocerebellar degeneration due to expansions of
polyglutamine in the ataxin protein. The retinal disease
often begins with granular macula progressively spreading
out to the whole retina, while the macula becomes
atrophic (Figure 3) [3]. Initially, the disease often presents
as an isolated retinal dystrophy; the characteristic macular
involvement and the importance of visual impairment in
a previously well seeing patient should lead to neurologi-
cal investigations.
• Ectodermal diseases. CRD is sometimes encountered
in:
❍ Amelogenesis imperfecta. This refers to several conditions
in which the tooth enamel is abnormal. One form of
amelogenesis imperfecta with autosomal recessive inher-
itance (OMIM # 217080) is associated with CRD and
abnormally shaped teeth [4-6].
❍ Hypotrichosis with juvenile macular dystrophy [7]. It is a
rare form of autosomal recessive alopecia associated with
macular dystrophy. Usually, the retinal impairment is
restricted to the macula but in a few instances it has been
reported to be a CRD [8].
❍ Dysmorphic syndromes. CRDs have been reported in
spondylometaphyseal dysplasia [9] and in cleft lip [10].
❍ Metabolic dysfunctions. CRD has been reported to occur
in several metabolic disease (thiamine-responsive mega-
loblastic anemia [11,12]; one case with a mitochondrial
mutation (T8993G) has been reported [13]. In addition,
infantile Refsum disease with augmented phytanic acid
Fundus of a 31 year-old patient with Bardet Biedl syndromeigure 2
Fundus of a 31 year-old patient with Bardet Biedl syndrome. 
The peripheral retina does not show any large lesion but the 
macula is atrophic.Fundus of a 45 year-old patient with cone rod dystrophy seg-regating with a loss- f-function mutati  (E1087X) in ABCA4i ure 1
Fundus of a 45 year-old patient with cone rod dystrophy seg-
regating with a loss-of-function mutation (E1087X) in ABCA4. 
Note the presence of various-shaped pigment deposits in the 
posterior pole with atrophy of the retina, while the retina 
appears less damaged in periphery (upper part of the photo-
graph).Page 3 of 7
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istic prominent macular involvement, and in Alport syn-
drome (deafness, progressive nephritis) the fundus shows
whitish flecks looking like crystals around the macula
rather than an authentic pigmentary retinopathy.
Etiology of non syndromic CRDs
Non syndromic CRDs are, like typical RP, genetically het-
erogeneous. Three Mendelian types of inheritance have
been reported. Today, there are 13 genes responsible for
non syndromic CRDs (10 cloned, 3 mapped). These genes
can be classified in several categories.
The 1st category includes genes mostly responsible for
CRDs cases. The predominant one encodes the homeobox
protein CRX, which controls rod and cone photoreceptor
cell differentiation and survival. Most CRX mutations
cause autosomal dominant CRD, with a prevalence esti-
mated at 5 to 10% of dominant CRDs [14,15]. The sever-
ity of the disease is highly variable with some mild cases
and some very severe cases. In fact, at this end of the spec-
trum, there have been a few reports of dominant Leber
congenital amaurosis (LCA) caused by CRX mutations
[16,17], a condition which is usually recessive, as well as
a few RPs. Two other genes have been found only in
CRDs. These are RIM1, reported in one family with auto-
somal dominant CRD [18] and HRG4, reported in one
family with uncertain inheritance [19]. Interestingly, both
encoded proteins are involved in photoreceptor synaptic
transmission.
The 2nd category includes genes mostly found in macular
dystrophies. Today, it comprises essentially one gene,
ABCA4, which is involved in the retinoid metabolism and
causes the Stargardt disease. Mutations in the ABCA4 gene
are responsible for 30 to 60% of the cases with autosomal
recessive CRDs [20-25]. In some cases, the disease begins
as a Stargardt macular dystrophy, which soon extends to
the periphery. In other cases, the disease starts as a diffuse
retinopathy with predominance of macular involvement.
It has been shown that the ABCA4 mutations linked to
CRDs are truncating mutations, often on both alleles,
whereas amino acid change mutations are more fre-
quently found in Stargardt disease. This suggests that
more deleterious truncating mutations are associated with
more severe conditions like CRD [26]. Belonging to this
2nd category, mutations of GUCA1A have been described
in one family with autosomal dominant CRD, while all
other GUCA1A mutations are responsible for cone dystro-
phies. The GUCA1A gene encodes a protein that activates
the guanylate cyclase (GC) [27]. GC itself is sometimes
involved also in CRDs (see below).
The 3rd category includes two genes mostly found in RP
cases. One codes for the outer segment protein
peripherin/RDS and is usually involved in autosomal
dominant RP. It is well known that there are inter- and
intra-familial phenotypic variations with RDS mutations
including cases of dominant macular dystrophy or domi-
nant CRD [28]. CRDs due to mutations in the RDS gene
are relatively moderate in comparison with autosomal
recessive CRDs, as the autonomy of patients is conserved
in early adulthood. The other gene codes for RPGR
(involved in opsin trafficking, particularly that of cone
opsins). RPGR is the major causative gene for X-linked
RPs, but it also accounts for some X-linked CRD with its
locus referred as COD1 or CORDX1 [29] and cone dystro-
phies. As for RPs, CRDs caused by mutations in the RPGR
gene are severe and diagnosed early in life. In addition to
RDS and RPGR, the CACNA1F gene, whose mutations
lead to X-linked congenital stationary night blindness, is
mutated in one CRD Finnish family previously mapped as
CORDX3 (or COD4) [30].
The 4th category includes genes found in LCA. Today,
there are three reported CRD families with mutations in
the RPGRIP1 gene [31] (autosomal recessive inheritance)
and AIPL1 [32] (autosomal dominant inheritance). These
genes are usually involved in the pathogenesis of LCA.
There are also several CRD families reported with muta-
tions in GUCY2D [33,34], which is the major causative
gene for LCA. In contrast to LCA patients, CRD patients
with GUCY2D-mutations have a dominant condition, the
mutations being restricted to exon 13 encoding the dimer-
ization domain of the guanylate cyclase.
Fundus of a 34 year-old patient with cone rod dystrophy due to Spinocerebellar Ataxia Type 7 (SCA7)igure 3
Fundus of a 34 year-old patient with cone rod dystrophy due 
to Spinocerebellar Ataxia Type 7 (SCA7). Note that the mac-
ular area, and also the mid periphery, are atrophic.Page 4 of 7
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autosomal dominant CRDs, the CORD1 gene (undeter-
mined localization) has been found in a Danish family
with CRD and mental retardation [35]. CORD4 has been
mapped in a Canadian family with CRD associated with
neurofibromatosis [36]. For autosomal recessive CRDs,
there are CORD8 mapped in a Pakistani family [37] and
CORD9 in a Brazilian family [38]. For X-linked CRDs,
CORDX2 has been mapped to Xq27 [39].
Taken together, it seems that most genes responsible for
CRDs are involved in other types of retinal dystrophies,
including RPs, macular dystrophies and cone dystrophies,
thereby placing CRDs in the center of the vast panel of ret-
inal dystrophies. One can therefore speculate that any
gene causing retinal dystrophy may potentially be
involved in CRD pathogenesis, and the challenge is to
understand the underlying mechanisms. It seems clear
that deleterious mutations of retinal dystrophy genes can
cause very severe diseases, and hence CRDs. However, it is
not yet clear why in some families, some members have
macular dystrophy or RP, whereas other members (with
the same mutations) have CRD. Likewise, the question
why some mutations in a gene lead to CRD whereas oth-
ers cause RP, remains unresolved for several genes.
Diagnostic methods
Clinical diagnosis is based on the early decrease of visual
acuity and photophobia, lesions in fundus, hypovolted
ERG traces with predominant cone involvement, and pro-
gressive worsening of these signs. Full field ERG is the key
test, particularly when patients are asymptomatic and
show normal fundus at early stages. It is important to
ascertain the diagnosis by repeating the examination one
or two years after it has been first established. Multifocal
ERG could be useful to follow precisely the functionality
of the central retina.
At present, a systematic molecular testing is not routinely
performed, due to the tremendous genetic heterogeneity
of the disease. However, rapid and large-scale mutation
screening techniques are developing and several laborato-
ries perform search for mutations in the most frequently
involved genes, including ABCA4, CRX, GUC1A; strategies
to test in a short time several dozen of genes for a single
patient DNA are emerging [23,40].
In some instances, molecular diagnosis for certain genes is
performed by the laboratories that have discovered them.
Differential diagnosis of non syndromic CRDs with other 
pigmentary retinopathies
CRDs are usually clearly differentiated from primary
peripheral retinopathies and macular dystrophies. How-
ever, CRD may sometimes share features with several clin-
ical entities.
Retinitis pigmentosa
• Typical RP (rod cone dystrophy, RCD). In typical RCD, the
diagnosis is easy because the first symptom is night blind-
ness. This symptom typically remains isolated for several
years with normal visual acuity before vision loss in day-
light becomes prominent. In the fundus, pigment depos-
its are located in the periphery.
• RP with early macular involvement. In some cases, RCD
has a typical slow progression but macular involvement
occurs quite early, with some loss of visual acuity. A dis-
ease history characterized by predominant night blind-
ness and prominent rod involvement on ERG supports
the diagnosis of RCD.
• Early onset RP or late stage RP. In cases associated with
early onset and severe RCD, the decrease in visual acuity
with macular involvement may also occur early. It is again
important to determine which sign, either night blindness
or loss in central vision, appeared first in the disease
course, and to perform ERG. The diagnosis may be partic-
ularly difficult when patients are examined at late stage. At
that time, the typical changes in ERG are undetectable.
Leber congenital amaurosis (LCA)
This disease is associated with a high degree of visual
impairment, which is already present at birth, and appears
either as a rod- or cone-predominant disease, or both.
Nystagmus, poor light fixation and reactivity, visual acuity
lower than 1/20 and flat ERG are cardinal signs of the dis-
ease. Differential diagnosis with early onset CRD may be
difficult because both diseases share the same clinical
signs. The presence of a lapse time of several years before
dramatic worsening of the visual disability will allow to
classify the disease as CRD rather than LCA.
Maculopathies
Large, extended maculopathies may be difficult to differ-
entiate from end stage CRD or RP. In all cases, the full
field ERG is a key investigation.
• Stargardt disease is a maculopathy in which peripheral
retina usually remains free of lesions. The disease is easy
to recognize with the presence of yellow flecks that may
cover the entire fundus (fundus flavimaculatus), hyperflu-
orescent macular lesions (bull's eye) and dark choroid on
the fluorescein angiography. However, there are extended
lesions in some late stage Stargardt cases, and in addition,
a number of CRD are caused by the "Stargardt gene",
ABCA4. In these cases, the early stage of the CRD may be
similar to Stargardt disease, but, in a decade, signs of
peripheral involvement occur.Page 5 of 7
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Main clinical signs are loss of visual acuity, photophobia,
dyschromatopsia, and exclusive cone involvement at
ERG. However, in some cone dystrophies, there may be
some rod involvement, particularly in late stage. In con-
trast to CRDs, rods remain at least partly spared at these
late stages, whereas they are non recordable in late stage
CRD. Another sign is the absence of macular lesions for
many years, even though the visual acuity is decreased.
Stationary retinal diseases
This is essentially achromatopsia, which is diagnosed on
the basis of mainly cone involvement (rod being not
entirely normal), the lack of disease evolution, and the
normal fundus.
Genetic counseling
Once the diagnosis CRD is made, patients should be
informed and familial surveys recommended. Genetic
counseling is always advised since all genetic forms can be
encountered in CRD. A precise phenotypic diagnosis is
always mandatory and is particularly useful in the absence
of familial history or in sporadic cases.
Antenatal diagnosis
Prenatal diagnosis can be performed in families in which
the responsible gene has been identified. However, prena-
tal diagnosis (amniocentesis or chorionic biopsy) raises
an ethical issue: whether the investigative risks associated
with these invasive prenatal procedures are justified in a
non life-threatening disease is questionable.
Management including treatment
Currently, there is no therapy that stops the evolution of
pigmentary retinopathies or restores the vision. However,
there are several therapeutic strategies aimed at slowing
down the degenerating process (light protection, vitami-
notherapy), treating the complications such as cataract,
macular edema, inflammation, and helping patients to
cope with the social and psychological impact of blind-
ness. In fact, management of CRDs is not different from
the management of typical RP. A particular emphasis
should be put on filtrating spectacles to minimize photo-
phobia and on low vision aid. Patients are often severely
visually disabled or legally blind by the end of the second
decade of life. Therefore, it is important that their educa-
tion focuses on an adapted professional occupation
(teaching, computer based activities, physiotherapist).
Unresolved questions
Cloned genes account for only a small part of the auto-
somal dominant CRDs cases and probably for half of the
autosomal recessive cases. Therefore, genes remain to be
discovered. Understanding the role of the encoded pro-
teins often requires many years. Today, for a number of
proteins, substantial information about their function is
available, while some of the proteins remain poorly
known.
A challenging issue is the elucidation of the precise steps
leading from a gene mutation to photoreceptor degenera-
tion. Data from animal models and clinical studies sug-
gest that photoreceptors die by apoptosis at a linear rate
throughout life (named the "one-hit hypothesis"), imply-
ing that they have a given probability to undergo apopto-
sis that remains constant from early to late stages of the
disease [41]. For certain genes or severe mutations, this
probability will be high, while for others it will be lower.
The results of experimental and clinical studies clearly
indicate that the mechanisms of photoreceptor degenera-
tion are multiple. In all genetic forms of CRDs studied
until now, data are incomplete. In addition, it is likely that
several apoptotic pathways are involved in the photore-
ceptor loss, sometimes concurrently, and this also needs
to be carefully investigated. This knowledge is crucial to
design therapies. The efficacy of various potential treat-
ments has to be proven in animal models and in humans.
For example, gene replacement therapy for RDS in mouse
improves photoreceptor ultrastructure, but there is no sig-
nificant effect on photoreceptor cell loss [42].
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